Key Points
- Natarajan Sethuraman sold 25,907 shares of Entrada Therapeutics at an average price of $15.39 on May 4 for about $398,709, reducing his holdings by 10.7% to 216,317 shares; the transaction was executed under a Rule 10b5-1 trading plan.
- Entrada is a clinical‑stage biotech with a market cap of roughly $613M; it reported a quarterly EPS of (‑$0.94) that beat expectations but had a large revenue miss, and analysts’ consensus is a Moderate Buy with an average price target of $19.00.
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) COO Nathan Dowden sold 15,000 shares of the firm's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $15.33, for a total transaction of $229,950.00. Following the completion of the sale, the chief operating officer owned 198,588 shares in the company, valued at $3,044,354.04. The trade was a 7.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Entrada Therapeutics Trading Up 8.9%
Shares of TRDA opened at $15.79 on Tuesday. Entrada Therapeutics, Inc. has a twelve month low of $4.93 and a twelve month high of $16.00. The firm's fifty day simple moving average is $12.72 and its 200-day simple moving average is $10.75. The firm has a market capitalization of $612.97 million, a price-to-earnings ratio of -4.56 and a beta of -0.09.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, beating analysts' consensus estimates of ($1.32) by $0.38. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. The business had revenue of $1.30 million for the quarter, compared to analyst estimates of $7.41 million. On average, analysts predict that Entrada Therapeutics, Inc. will post -4.22 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on the stock. Oppenheimer lifted their price target on shares of Entrada Therapeutics from $21.00 to $23.00 and gave the stock an "outperform" rating in a research note on Monday, April 6th. Cantor Fitzgerald assumed coverage on shares of Entrada Therapeutics in a research note on Wednesday, April 1st. They set an "overweight" rating on the stock. Weiss Ratings reiterated a "sell (d)" rating on shares of Entrada Therapeutics in a research note on Friday, March 27th. Guggenheim upgraded shares of Entrada Therapeutics to a "strong-buy" rating in a research note on Wednesday, February 11th. Finally, HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $19.00.
Get Our Latest Stock Report on Entrada Therapeutics
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. Hsbc Holdings PLC increased its stake in Entrada Therapeutics by 83.1% in the first quarter. Hsbc Holdings PLC now owns 38,137 shares of the company's stock valued at $472,000 after purchasing an additional 17,304 shares during the period. Invesco Ltd. increased its stake in Entrada Therapeutics by 41.1% in the fourth quarter. Invesco Ltd. now owns 41,033 shares of the company's stock valued at $422,000 after purchasing an additional 11,958 shares during the period. XTX Topco Ltd increased its stake in Entrada Therapeutics by 26.4% in the fourth quarter. XTX Topco Ltd now owns 117,668 shares of the company's stock valued at $1,210,000 after purchasing an additional 24,589 shares during the period. Wellington Management Group LLP increased its stake in Entrada Therapeutics by 9.5% in the fourth quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company's stock valued at $10,740,000 after purchasing an additional 90,339 shares during the period. Finally, Sphera Funds Management LTD. acquired a new position in Entrada Therapeutics in the fourth quarter valued at $1,140,000. 86.39% of the stock is currently owned by institutional investors and hedge funds.
Entrada Therapeutics Company Profile
(
Get Free Report)
Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.
The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
